TAK · Takeda Pharmaceutical Co Ltd
Market Cap
$58.66B
Shares
3.19B
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
4.58T
+7.5%
FY2025
Net Income
107.93B
-25.1%
FY2025
Gross Margin
65.51%
-1pp
FY2025
Operating Margin
7.48%
+2.5pp
FY2025
Operating Cash Flow
1.06T
+47.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| JPY | 4.58T | 4.26T | 4.03T | 3.57T | 3.2T | 3.29T | 2.1T | 1.77T | 1.73T |
| JPY | 1.58T | 1.43T | 1.24T | 1.11T | 994.31B | 1.09T | 651.73B | 495.92B | 558.76B |
| JPY | 730.23B | 729.92B | 633.33B | 526.09B | 455.83B | 492.38B | 368.3B | 325.44B | 312.3B |
| JPY | 1.1T | 1.05T | 997.31B | 886.36B | 875.66B | 964.74B | 717.6B | 628.11B | 619.06B |
| JPY | 761.4B | 728B | 664.4B | 583.15B | 559.67B | 583.65B | 247.69B | 182.13B | 171.43B |
| JPY | 342.59B | 214.08B | 490.51B | 460.84B | 509.27B | 100.41B | 237.69B | 241.79B | 155.87B |
| JPY | 210.07B | 219.85B | 169.7B | 166.61B | 248.63B | 165.01B | 83.29B | 31.93B | 23.25B |
| JPY | 175.08B | 52.79B | 375.09B | 302.57B | 366.24B | -60.75B | 127.61B | 217.21B | 143.35B |
| JPY | 66.94B | -91.41B | 58.05B | 72.41B | -9.94B | -105.04B | -7.47B | 30.5B | 27.83B |
| JPY | 107.93B | 144.07B | 317.02B | 230.06B | 376.01B | 44.24B | 135.19B | 186.89B | 114.94B |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2025: $207.57B in buybacks, $2.15T in dividends.